X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4783) 4783
Book Chapter (2) 2
Dissertation (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
Book Review (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4141) 4141
male (2803) 2803
female (2526) 2526
pyrroles - therapeutic use (2206) 2206
middle aged (2138) 2138
pyrroles - adverse effects (1974) 1974
aged (1663) 1663
atorvastatin calcium (1439) 1439
adult (1393) 1393
pyrroles - administration & dosage (1302) 1302
treatment outcome (1092) 1092
oncology (1027) 1027
animals (962) 962
indoles - adverse effects (945) 945
heptanoic acids - therapeutic use (910) 910
indoles - therapeutic use (868) 868
sunitinib (854) 854
pyrroles - pharmacology (852) 852
atorvastatin (819) 819
pharmacology & pharmacy (758) 758
carcinoma, renal cell - drug therapy (710) 710
kidney neoplasms - drug therapy (670) 670
heptanoic acids - adverse effects (651) 651
cancer (616) 616
statins (609) 609
antineoplastic agents - therapeutic use (608) 608
antineoplastic agents - adverse effects (590) 590
heptanoic acids - administration & dosage (587) 587
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (568) 568
care and treatment (541) 541
aged, 80 and over (502) 502
indoles - administration & dosage (490) 490
drug therapy (458) 458
dose-response relationship, drug (453) 453
cardiac & cardiovascular systems (448) 448
therapy (443) 443
double-blind method (439) 439
cholesterol (438) 438
pyrimidines - therapeutic use (433) 433
analysis (426) 426
risk factors (415) 415
efficacy (414) 414
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (412) 412
kidney neoplasms - pathology (392) 392
research (381) 381
medicine & public health (373) 373
safety (365) 365
simvastatin (364) 364
anticholesteremic agents - therapeutic use (354) 354
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (351) 351
drug therapy, combination (347) 347
tyrosine kinase inhibitor (342) 342
mice (336) 336
time factors (336) 336
heptanoic acids - pharmacology (335) 335
niacinamide - analogs & derivatives (330) 330
cholesterol, ldl - blood (324) 324
pyrroles - pharmacokinetics (323) 323
rats (321) 321
retrospective studies (321) 321
medicine, general & internal (318) 318
pyrimidines - adverse effects (317) 317
abridged index medicus (315) 315
prospective studies (309) 309
metastasis (304) 304
endothelial growth-factor (300) 300
expression (300) 300
interferon-alpha (300) 300
protein kinase inhibitors - therapeutic use (292) 292
disease-free survival (291) 291
protein kinase inhibitors - adverse effects (289) 289
drug administration schedule (284) 284
antineoplastic agents (279) 279
anticholesteremic agents - adverse effects (278) 278
clinical trials (272) 272
antimitotic agents (265) 265
young adult (264) 264
sorafenib (263) 263
bevacizumab (255) 255
hypercholesterolemia - drug therapy (255) 255
carcinoma, renal cell - pathology (251) 251
survival (250) 250
urology & nephrology (250) 250
follow-up studies (247) 247
carcinoma, renal cell (246) 246
antineoplastic agents - administration & dosage (244) 244
prevention (239) 239
angiogenesis inhibitors - adverse effects (238) 238
inflammation (231) 231
internal medicine (231) 231
angiogenesis inhibitors - therapeutic use (229) 229
renal cell carcinoma (225) 225
health aspects (223) 223
clinical trials as topic (222) 222
risk (220) 220
hypertension (217) 217
chemotherapy (216) 216
drug interactions (216) 216
sulfonamides - therapeutic use (216) 216
disease (215) 215
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4614) 4614
French (48) 48
German (41) 41
Japanese (41) 41
Chinese (25) 25
Spanish (23) 23
Russian (15) 15
Italian (12) 12
Dutch (7) 7
Hungarian (5) 5
Portuguese (4) 4
Czech (2) 2
Danish (2) 2
Polish (2) 2
Swedish (2) 2
Croatian (1) 1
Korean (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0332, 2016, Volume 56, Issue 3, pp. kew442 - 425
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
...  REVIEWS Neurological adverse effects caused by cytotoxic and targeted therapies David Schiff, Patrick Y. Wen and Martin J. van den Bent Abstract... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 06/2016, Volume 27, Issue 5, pp. 383 - 397
.... A systematic review was conducted to assess the clinical efficacy, safety and effect of all first-line treatments evaluated to date on health-related quality of life (HRQoL... 
Metastatic renal cell carcinoma | First-line treatment | Systematic review | Advanced renal cell carcinoma | Treatment-naive patients | TARGETED THERAPY | RESPONSE CRITERIA | PAZOPANIB | PLUS INTERFERON-ALPHA | metastatic renal cell carcinoma | OPEN-LABEL | systematic review | SORAFENIB | advanced renal cell carcinoma | PHASE-III TRIAL | ONCOLOGY | DOUBLE-BLIND | SUNITINIB | PHARMACOLOGY & PHARMACY | first-line treatment | QUALITY-OF-LIFE | treatment-naive patients | Niacinamide - analogs & derivatives | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Carcinoma, Renal Cell - psychology | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Pyrroles - adverse effects | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Imidazoles - adverse effects | Interferon-alpha - therapeutic use | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Randomized Controlled Trials as Topic | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Pyrimidines - adverse effects | Quinazolines - adverse effects | Quality of Life | Sulfonamides - adverse effects | Indoles - therapeutic use | Kidney Neoplasms - pathology | Interferon-alpha - adverse effects | Quinolines - therapeutic use | Indazoles - adverse effects | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Quinolines - adverse effects
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article